Core Scientific stock has delivered a 61.1% return over the past year, yet the broader valuation checks currently lean toward the shares looking expensive rather than clearly cheap.

• A 61.1% one year gain highlights how strongly expectations have shifted for Core Scientific and raises the bar for what the current price already assumes.
• The long term AI infrastructure agreements with AMD can support confidence in future data center revenue, while heavy upfront investment and execution risk on new data center build outs may weigh on how investors think about valuation.
• Core Scientific scores 0 out of 6 on Simply Wall St's broader valuation checks, which suggests the stock does not screen as a straightforward bargain based on those metrics 0/6.

The issue now is whether Core Scientific's current share price already reflects these AI growth ambitions, or if the recent pullback has created a more reasonable entry point.

Does Core Scientific Look Pricey on Sales?

P/S is often a useful way to look at Core Scientific because the company is focused on high capital intensity and revenue growth rather than current earnings or free cash flow.

Core Scientific currently trades on a P/S of 15.9x, which is much higher than the broader software industry average of 3.6x. It also sits well above the 7.4x peer group average and the modelled fair P/S ratio of 8.1x that reflects the company’s risk profile, margins and market positioning.

The long term AI infrastructure deal with AMD and the shift toward data center leasing help explain why investors are willing to pay such a rich sales multiple, despite ongoing losses and heavy investment. Even so, the gap between the current 15.9x and the 8.1x fair ratio suggests a lot of optimism is already embedded in the Core Scientific share price on this metric.

On the P/S multiple, the stock currently screens as overvalued relative to both its tailored fair ratio and sector benchmarks.

The Core Scientific Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this Core Scientific valuation puzzle leaves off. They explain which combinations of future growth, margins and earnings would need to occur for the stock to be worth materially more or less than today’s price. Each one sets out a fair value as a thesis about the business that you can follow over time, rather than relying on a single static snapshot. These are available on Simply Wall St's Community page.

One of the top community narratives on Core Scientific: 39% undervalued

"Core Scientific secured a major HPC contract with CoreWeave, with a total revenue potential of $8.7 billion over a 12-year term, significantly boosting future revenue compared to their current levels…"

Do you think there's more to the story for Core Scientific? Head over to our Community to see what others are saying!

The Bottom Line

Core Scientific screens as overvalued on the P/S multiple, with the current sales valuation sitting well above both sector averages and the tailored fair ratio. The stock now hinges less on whether it is cheap and more on whether future execution in AI and data center leasing can live up to the expectations already priced in. For investors, the key question is whether Core Scientific can turn heavy investment and long term contracts into durable, profitable growth that eventually makes the current multiple look reasonable rather than stretched.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.